STSA Satsuma Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

   SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference and invites investors to participate via webcast or in-person in Miami, FL on May 24 -25, 2022. Please see additional details below:
   

   
   H.C. Wainwright Global Investment Conference (Hybrid Conference)

   	Date:	Tuesday, May 24th
   	Time:	4:00 p.m. (ET)
   	Speaker:	John Kollins, President & CEO of Satsuma Pharmaceuticals,

   …

   View Full Article
2. 10 May 2022 Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

   - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 -
   

   - New Drug Application (NDA) submission anticipated in Q1 2023 -

   - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half of 2023 -

   SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the first quarter of 2022 and summarized recent business highlights.

   "We are pleased to report continued…

   View Full Article
3. 15 March 2022 Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

   - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 -
   

   - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 -

   SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full year ended December 31, 2021 and summarized its business highlights.

   "The coming twelve months promise to be eventful and marked…

   View Full Article
4. 03 March 2022 Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting

   SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that four abstracts highlighting STS101 and its differentiating features were selected for presentation and will be shared at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2 to April 7, 2022. Full abstracts are now available on the AAN website.         
   

   Title:	Pharmacokinetics and Safety of STS101, A Novel Investigational DHE Powder Drug-Device Combination in Healthy Subjects
   Abstract:	521
   Poster Presentation #:

   …

   View Full Article
5. 08 February 2022 Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference

   SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the 11^th Annual SVB Leerink Global Healthcare Conference and invites investors to participate via webcast. Please see additional details below:

   11^th Annual SVB Leerink Global Healthcare Conference (virtual)

   Date:	Thursday, February 17th
   Time:	3:00 p.m. (ET)
   Speaker:	John Kollins, President & CEO of Satsuma Pharmaceuticals, Inc.
   Format:	Fireside Chat
   Webcast:	Registration

   …

   View Full Article